Objectives: A primary outcome in oncology trials is overall survival (OS). However, to estimate OS accurately requires a sufficient number of patients to have died, which may take a long time. If an alternative endpoint is sufficiently highly correlated with OS, it can be used as a surrogate. Progression-free survival (PFS) is the surrogate most often used in oncology, but does not always satisfy the correlation conditions for surrogacy.
FUNDING
The Pharmaceutical Oncology Initiative (POI) of the Association of the British Pharmaceutical Industry (ABPI) commissioned the Office of Health Economics (OHE) in April 2016 to undertake a landscape study on methods and approaches to extrapolation from clinical endpoints measured in trials involving overall survival.
INTRODUCTION
Outcomes from clinical and other healthcare trials of most interest to patients and health systems are usually increases in the length and quality of life as a result of treatment.
This poses a problem, because to estimate overall survival (OS) sufficiently accurately often requires long-term follow-up. Direct extrapolation of OS to encompass those patients who had not died by the end of the follow-up period may be carried out.
Although it is the preferred method of the UK´s National Institute of Health and Care Excellence (NICE), its use is not always satisfactory (2, 3) . An alternative is to use progression-free survival (PFS) as a surrogate outcome. Trials with an adequate surrogate endpoint can be shorter and involve fewer patients, and can thus help to bring a new drug or treatment to the market sooner, or allow products to be brought to market where the costs of a trial using OS would not be justified by the expected returns. This is beneficial to patients and health systems, and improves returns to manufacturers.
However, these benefits are achieved at the expense of a less accurate measure of final outcome than would occur by waiting for data such as OS to become available. Thus there is a trade-off between time elapsed from the end of study (excluding follow-up) before information becomes available, and the accuracy of the information about the benefits of treatment. This paper analyses the methodologies and challenges faced when using PFS as a surrogate for OS in oncology.
METHODS
Davis, Tappenden (1) conducted a literature review on the use of surrogate endpoints in oncology up to the end of 2011. They identified 266 articles, using citation searching to identify relevant papers from an initial list of three papers already known to the authors.
They said a systematic literature review was not feasible, because an exploratory search returned a very large number of references (over 3,000), and because any attempt to make the search more specific resulted in many relevant papers being excluded.
Davis, Tappenden (1) included all reviews that examined a statistical relationship between OS and either PFS or time to progression (TTP) and considered any form of treatment where curing the disease was not expected. Nineteen key articles concerning the relationship between PFS/TTP and OS in advanced/metastatic cancer were included.
We updated the review conducted by Davis, Tappenden (1) to 2016 using similar search methods and selection criteria to preserve as much comparability as possible, and using the 19 papers identified by them as our key papers upon which to base our citation search. We considered only articles in which PFS was mentioned, and excluded those articles that analysed only TTP. Davis, Tappenden (1) did not include radiographic progression-free survival (rPFS) studies, and so neither did we. A previous follow-up of Davis, Tappenden (1) was carried out by Ciani, Davis (4) . Our analysis differs from that of Ciani, Davis (4) as our aim has additionally been to examine the statistical methodologies most commonly applied as well as the main challenges faced by authors when assessing the validity of PFS as a surrogate.
In August 2016, we conducted a Google Scholar citation search from January 2012 to June 2016, identifying a total of 790 articles which had cited any of the original 19 key articles identified by Davis, Tappenden (1). We applied four inclusion criteria: 1) mentioned PFS and OS in the title; or 2) mentioned PFS as a surrogate (including surrogate + outcome/endpoint/measure); or 3) analysis of possible surrogate measures in cancer; or 4) analysed endpoints for cancer. An additional seven articles were excluded because they are reviews of previous studies of PFS surrogacy. After applying a series of exclusion criteria (Figure 1 ), 48 articles were included in the analysis.
The 19 papers reviewed by Davis, Tappenden (1) and the 48 in this paper were mostly summaries of many studies. For each study within a paper, there was a single aggregate data point pair, the average/median PFS and the average/median OS. This pair of points was then used as one observation in an analysis that pooled all such pairs from the many studies considered in the paper. The sample size for the estimated correlations or regression parameters equals the number of studies considered by the paper. Such data are known as aggregated clinical trial data (ACTD), in which large amounts of data (all the data points of individuals within each trial) have been ignored. In both Davis, Tappenden (1) and our paper, a minority of analyses used unaggregated source data.
That is, each patient within the study has a pair of observations which is brought together in a sample, the size of which is the number of patients, for estimating correlations and regression parameters. Such data are known as individual patient data (IPD). Information regarding methodology, data and factors affecting the relationship between PFS and OS were extracted. Author affiliation and publication journal were also collected by KHV. The quality and accuracy of the extraction was verified by AF.
RESULTS
The 2012-2016 results from this review are very similar to those of Davis, Tappenden (1). Davis, Tappenden (1) usually found a positive correlation between PFS/TTP and OS for individual patients, individual trial arms and the treatment effect between trial arms: only 10.5% (2/19) of articles did not support the idea that PFS/TTP could be a useful surrogate for OS. However, the size of the correlation and its statistical significance varied considerably across studies, particularly between cancer types. The authors attributed this variation to the dissimilarities in patient characteristics from study to study, such as tumour type, line of therapy, and diversity of treatment methods.
We classified the results into three groups: 1) papers that explicitly mentioned that PFS is a good surrogate for OS, 2) those that indicated that PFS could be a good surrogate only under certain conditions, and 3) those that concluded that PFS is not a good surrogate for OS. Davis, Tappenden (1) (7/12) and our (17/32) analysis both indicate that around 55% of the articles using ACTD from multiple trials support PFS surrogacy.
Eight of the remaining 15 articles in our study do not support surrogacy, while seven articles support PFS surrogacy only under particular conditions (e.g. treatment line).
The lack of IPD is evident if we consider that around 35% of the articles found both by Davis, Tappenden (1) (7/19) and by this review (16/48) include IPD data (Table 1) .
Among the 10 articles that used solely IPD in our review, four supported surrogacy, 5 did not and one supported surrogacy for treatments that have a major impact on PFS.
Moreover, six of the ten IPD articles in our review were based on information collected in a single Japanese institution, which indicates that the conclusions should be viewed with caution (5-10).
Methodologies and statistical results
In analysing the relationship between PFS and OS, the most usual preference has been for the use of correlation such as Spearman, Pearson or Kendall's (71%-34/48) and weighted or unweighted linear regression (73%-35/48) ( Table 2 ), comparable to the findings of Davis, Tappenden (1). Moreover, like Davis, Tappenden (1), we found that many different variations in methodology have been applied which makes it difficult to compare the results of studies (e.g. Aboshi, Kaneko (11) and Bria, Massari (12), Table   2 ). Those articles that include ACTD mostly use median PFS and median OS, but in some cases the estimation uses a logarithmic transformation of the variables (27) . In the case of IPD articles, the relationship between the actual values per patient of PFS and OS is used to estimate the predictive capacity of PFS.
The effect of treatment in changing PFS to predict the effect of treatment in changing OS is explored throughout the analysis of ACTD. Here it is common to compare hazard ratios (HRs); however, we also identified articles in which the differences in median PFS and OS were examined (13, 33, 41) .
By comparing the distribution of the observations by Surrogacy (Appropriate surrogate (AP); Depends on particular factors (DPF); PFS is not an appropriate surrogate (NoAP)) (Table 1 ) with the distribution of the observations split into two depending on the type of data (ACTD, IPD or Both), we observe a significant relationship (Fisher's Exact Test 0.039; Pearson's Chi-squared 0.043) between Surrogacy and Type of data, which suggests that the availability of IPD data affects the final conclusion.
Surrogate threshold effect (STE)
STE is defined as the minimum treatment effect on the surrogate necessary to predict a non-zero effect on the true endpoint (47) . It is normally presented as a Hazard Ratio (Table 3) .
Weaknesses of the current approaches

1) Lack of rigour in applying methodology.
Weighted linear regression, the most frequently-used method of analysis, is based on assumptions that are not tested in the majority of articles when analysing surrogacy. In only a few such cases was the type of model mentioned (14) . Exceptions are Félix, Aragão (16) that use the Generalized Method of Moments (GMM) to control for heteroscedasticity; and Johnson, Liauw (35) whose results showed unsatisfactory diagnostics with non-normality and heteroscedasticity in the residuals.
Although linear regression assumptions should be so widely known as to be considered irrelevant to report them, their absence leaves many analyses open to the suggestion of failure to handle complications, such as the presence of outliers. Clear outliers are shown in Yoshino, Imai (9) and Moriwaki, Yamamoto (38) . Only 23% (11/48) of studies consider or mention outliers. In five of the 11 cases authors test the sensitivity of the results by applying a 'leave-one-out' strategy (26, 47, 49, 52) . The six remaining articles test the sensitivity of the results by excluding those trials that are considered outliers (13, 16, 23, 24, 32, 36) .
Publication bias could also have a significant impact on the results, particularly for ACTD.
Out of the 31 articles that include systematic literature reviews, 11 mentioned publication bias as a possible limitation of the study while an additional six articles included a step to overcome the possible bias. Among the six, some articles considered both published and unpublished clinical trials (15, 30, 40) ; the others analysed the extent to which bias represents a problem using Egger's regression test (13, 24, 41) .
2) Apparently inconsistent conclusions
The German Institute of Quality and Efficiency in Health Care (IQWiG) framework still supported PFS as a surrogate for OS, a decision that appears to be influenced by the slope of the linear regression. The slope suggests that a one-month gain in PFS will be linked to three weeks' prolongation in OS. However, the reasons for concluding that the surrogacy is supported remain unclear. 
Challenges for analysing PFS as a surrogate of OS
Based on the variables included as part of sensitivity analyses or that have been included in multivariate analyses in the papers included in this review, we identify a group of factors that could affect the relationship between PFS and OS and appear in at least five studies. (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) 26, 32, 33, 35, 36, 38, (40) (41) (42) 47, 49, 50) The literature suggests that the relationship between PFS and OS can be different within the same cancer trial depending on the treatment applied or the therapy selected.
1) Type of treatment and/or therapy
2) Treatment line (14, 21, 22, 25, 26, 28, 33, 34, 36, 40, 41, 49, 52) In some cases the analysis cannot validate the surrogacy for first line therapy, as distinct 3) Year of the trial (11, 13, 15, 16, 18, 19, 22, 28, (31) (32) (33) (34) 40) The importance of the year in which the clinical trial was conducted or published was explained by the number of drugs available having increased (11 and because the criteria applied to measure progression have changed (e.g. RECIST published in 2000 was modified in 2010 to mRECIST (54)). (10, 11, 16, 18, 21, 26, 32, 34, 39, 52) As in Davis, Tappenden (1), the results from the validation of PFS as a surrogate point for OS vary substantially between cancer types. Six out of 16 articles for lung cancer conclude that PFS is not an appropriate surrogate for OS, and consistency does not improve when we consider the line of therapy and the phase of the clinical trial. This might be related to the fact that the criteria for supporting surrogacy differ considerably between studies. Additionally, it might not be just the observed relationship that is changing between studies. This suggests a need to standardise criteria.
4) Sub-group of patients or tumour type
5) Definition of PFS and other measures
Disease progression is often defined differently between clinical trials. This heterogeneity (11, 14, 15, 28, 33, 40) A reason given to explain geographical differences in trial results is the variation in comparator (i.e. standard) treatments between Asian and occidental countries. In addition, in advanced gastric cancer, Shitara, Ikeda (15) pointed out a number of differences in tumour characteristics and practice patterns (e.g. surgery and chemotherapy) that have been identified between Asian and occidental countries.
6) Geographical context
7)
Crossover (13, 23, 30, 33, 41) Some clinical trials allow crossover to the experimental regimen upon disease progression. This hinders the analysis of the treatment effect on OS. Eighteen out of the 32 articles that use ACTD mentioned crossover while six articles considered it during the estimation. For renal cell carcinoma, Delea, Khuu (13) indicate that the link between the effect of the treatment on PFS and the effect of the treatment on OS was stronger in studies that did not allow crossover. In melanoma, Flaherty, Hennig (23) suggested that correlation coefficients for the nine trials without crossover were significant and more than 7 percentage points higher than with crossover. Hotta, Suzuki (30) , in studying NSCLC, suggest that for clinical trials in which the median proportion of crossover was lower than 1%, the association between the HRs of PFS and OS was strong. Kim and Prasad (56), identified by Davis, Tappenden (1), evaluated previous publications to assess the strength of the surrogate-survival correlation among cancer drugs approved.
They found no significant differences in survival benefit between clinical trials with or without crossover. They suggest that the results are opposed to the commonly-shared idea that crossover masks OS benefits, possibly because crossover prevents observation of late toxicity. Contrary to other studies, in an analysis of colorectal cancer trials, Adunlin, Cyrus (33) found that among crossover trials the strength of the association between PFS and OS was higher.
Characteristics of post-progression survival
Characteristics The lack of any substantial proportionate increase in the number of articles including IPD data between Davis, Tappenden (1) study and our analysis suggests the rate of progress in this field is being hampered by an unwillingness by most pharmaceutical companies to provide IPD data to independent and well-qualified researchers for analysis or even to report analyses based on IPD when those data have routinely been collected.
Nevertheless, some progress in the topic has been observed, e.g. firms have joined recent initiatives such as clinicalstudydatarequest.com or project data sphere that allows researchers to analyse pooled IPD data sets.
The existence of heterogeneity in the definition of progression among clinical trials and a lack of clear information in the clinical trial reports as to how disease progression was evaluated (15, 17, 40) indicate that there is a need to standardise clinical trial protocols to provide comparability between trials for the same cancer type.
Finally, our search process found additional evidence that went beyond the scope of Davis, Tappenden (1) analysis. Stevens, Philipson (60) outlined an economic approach which bears on both clinical effectiveness and on cost effectiveness, suggesting a framework for factoring the use of surrogates into the decision-making process. Perhaps surprisingly, the benefits (or costs) of earlier adoption of a new technology that the use of a surrogate endpoint will usually allow are not taken into consideration when assessing new treatments. The longer the lag between the results of a trial using a surrogate endpoint rather than OS, the greater the additional benefits of using a surrogate should be, provided the surrogate is valid and that subsequent treatments do not act as confounders. However, as Davis Tappenden (1) explain, even when strong consistent evidence supporting a correlation between the treatment effects is available, it is unclear how that should be converted into a quantified relationship between PFS and OS treatment effects within a cost-effectiveness model.
CONCLUSION
The analysis strongly suggests that the use of IPD to assess surrogacy should increase.
A case could be made for release of all IPD as a condition of publication. As in Davis, Tappenden (1), our findings show that the availability of such information has been limited, though recent data-sharing initiatives may be changing that.
There is a high variation in the characteristics of the methodologies and little apparent consistency in what should be considered appropriate statistical estimation methodology.
Thus the need for standardisation that allows for more consistent results.
Standardization, in the form of adhering to common definitions, statistical techniques and a checklist of necessary items in reporting results, would often be virtually costless.
This could facilitate the use of PFS by policy-makers --if it were deemed appropriate --based upon standardised validation methodology, and could increase both the speed and accuracy of their decision-making.
Many of the factors that affect the validation of surrogacy are related to the length and characteristics of post-progression survival. Procedures for gathering information on factors affecting the post-progression management of a disease should be described in protocols for following-up clinical trial patients, making it possible to derive stronger conclusions from statistical analysis.
Some limitations of the study need to be mentioned. First, it is not a full literature review. We conducted a citation search based on Davis, Tappenden (1) 19 studies that we assume captured all relevant articles. Discussions with experts and comparisons with previous systematic reviews suggest that no relevant article has been excluded from the analysis. Second, this is also not a systematic literature review of any particular cancer type. Therefore, analysing whether PFS should or should not be used in any particular case was outside of the scope of this analysis. It is recommended that the factors that affect the relationship between PFS and OS by cancer type should be analysed in order to understand the particular challenges faced in each case. Third, for pragmatic reasons, our exclusion of TTP ignores the possibility that the names of TTP and PFS have in error been used interchangeably (61) .
Finally, in addition to using one of the frameworks promoted by Ciani, Davis (4) to ensure a higher standard of validation of the strength of evidence, both researchers and policy-makers in an area that makes use of surrogate endpoints need to be aware that the statistical methodology must be properly understood and documented. The importance that validating PFS as a surrogate for OS may have on allowing patients to access new health technologies more quickly should not be undermined by a poor knowledge of the methodology applied. The results of this study are broadly in line with those of Kemp and Prasad (62) who have concluded that the use of surrogate outcomes should be limited to situations where a surrogate has demonstrated robust ability to predict meaningful benefits, or where cases are dire, rare or with few treatment options.
